New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07374848
Summary
This is the first human study of an experimental cancer drug called ZL-6201. The main goal is to find a safe dose and see how the body processes the drug in adults with advanced sarcoma or certain other solid tumors that have stopped responding to standard treatments. Researchers will also look for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zai Lab Site 02006
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Zai Lab Site 02026
RECRUITINGSarasota, Florida, 34232, United States
Contact
Conditions
Explore the condition pages connected to this study.